alexa Inhibition And Disaggregation Of Human Lysozyme Amyloid Aggregates By Levodopa
ISSN: 2329-6895

Journal of Neurological Disorders
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

International Conference on Neurological Disorders & Stroke and Neurooncology
April 24-25, 2017 Dubai, UAE

Saima Nusrat and Rizwan H Khan
Aligarh Muslim University, India
Posters & Accepted Abstracts: J Neurol Disord
DOI: 10.4172/2329-6895-C1-018
Abstract
Amyloid related neurodegenerative diseases and non-neuropathic systemic amyloidosis have attracted much research efforts; however no curative drugs have been known till date other than the symptomatic cure. Therapeutic compounds that can either inhibit or disaggregate fibrillar species have been explored and many more are yet to be discovered. The current research describes an inclusive biophysical, microscopic and computational study establishing that L-3, 4-dihydroxyphenylalanine (Levodopa) to be promising against the inhibition and disaggregation of thermally induced amyloid fibrillation of human lysozyme (HL). The IC50 value of Levodopa was estimated to be 63.0±0.09 μM. Levodopa interferes amyloid fibrillation by forming hydrophobic interaction and hydrogen bond formation with the amino acid residues present in the amyloid fibril forming prone region of HL as explained by molecular simulation results. Levodopa was also found to disaggregate mature amyloid fibrils into unordered species and the DC50 value was calculated to be 19.95±0.06 μM. Thus, Levodopa and compounds with similar structure could be operative as a strong inhibitor towards the therapeutic development against systemic amyloidosis.
Biography

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords